Zura Bio appoints Dr. Kiran Nistala as EVP, effective Nov 27, 2023

Zura Bio Ltd

Dr. Nistala appointed Executive Vice President, effective November 27, 2023.
Annual base salary of GBP £320,000; eligible for discretionary bonus targeting 40% of base.
Company will recommend grant of 350,000 share options under 2023 Equity Incentive Plan.
Options vest 1/4 on first anniversary, then 1/36 monthly over 36 months; full vest at 4 years.
Dr. Nistala previously VP late-stage clinical development at AstraZeneca; also held senior roles at GSK.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Kiran Nistala

Executive Vice President

ZURA · Zura Bio Ltd

Effective: 2023-11-27
Filed: December 6, 2023, 6:59 PM ET

On November 30, 2023, Zura Bio Limited (the “Company”) appointed Dr. Kiran Nistala as Executive Vice President, effective as of November 27, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Kiran Nistala was appointed as Executive Vice President at Zura Bio Ltd.

Action: appointed
Role: Executive Vice President

Exact text from the filing

On November 30, 2023, Zura Bio Limited (the “Company”) appointed Dr. Kiran Nistala as Executive Vice President, effective as of November 27, 2023

View on SEC.gov

Zura Bio Ltd filing history →

Source: SEC EDGAR

accession 0001104659-23-124000

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.